



Norbert Schmitz

Contact

Norbert Schmitz

Publications (7)

Borchmann P, Bentz M, Keller U, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Hitz F, Topp M, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. *Lancet* 2017; 390:2790-2802.

Paul U, Stein H, Hansmann M, Möller P, Szczepanowski M, Burkhardt B, Pfreundschuh M, Schmitz N, Loeffler M, Trümper L, Siebert R, Cogliatti S, Feller A, Rosenwald A, Richter J, Stuhlmann-Laiasz C, Kreuz M, Nagel I, Horn H, Staiger A, Aukema S, Hummel M, Ott G, Spang R, Klapper W. Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC. *Leuk Lymphoma* 2017:1-9.

Staiger A, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, Hansmann M, Lenze D, Ziepert M, Horn H, Scott D, Barth T, Bernd H, Feller A, Klapper W, Szczepanowski M, Hummel M, Stein H, German High-Grade Lymphoma Study Group. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. *J Clin Oncol* 2017; 35:2515-2526.

Horn H, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G, Möller P, Schmelter C, Hansmann M, Ziepert M, Becher C, Barth T, Bernd H, Feller A, Klapper W, Hummel M, Stein H, German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. *Blood* 2013; 121:2253-63.

Thieblemont C, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Trougouboff P, Cogliatti S, Briere J, Mounier N, Voelker H, Cuccuini W, Hirschaud E, Rosenwald A, Jack A, Sundstrom C, Gisselbrecht C. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. *J Clin Oncol* 2011; 29:4079-87.

Ott G, Frank M, Hansmann M, Barth T, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Loeffler M, Müller-Hermelink H, Stein H, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd H, Thorns C, Feller A, Lenze D, Hummel M, Rosenwald A. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. *Blood* 2010; 116:4916-25.

Bernd H, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Höller S, Löffler M, Feller A, Barth T, Müller-Hermelink H, Rosenwald A, Ziepert M, Thorns C, Klapper W, Wacker H, Hummel M, Stein H, Hansmann M, Ott G, German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. *Haematologica* 2009; 94:1569-80.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch